Creative Biolabs is a world leader in the field of in vitro diagnostic (IVD) antibody development. With our extensive experience and advanced technology platforms, we provide a range of IVD antibody development services against the prostate-specific antigen (PSA) marker for the diagnosis of prostate cancer.
Prostate-Specific Antigen (PSA)
Prostate-specific antigen (PSA), also called kallikrein-3, is a glycoprotein produced by normal, as well as malignant, cells of the prostate gland. It functions to liquefy serum, promote sperm motility and dissolve cervical mucus. PSA was discovered in the 1970s by Richard Ablin; a discovery that subsequently led, in his opinion, to a ‘profit-driven public health disaster'. The possibilities for early detection of prostate cancer were recognized in 1991. In the past two decades, PSA screening for the diagnostics of prostate cancer has been widely performed.
PSA as Marker of Prostate Cancer
Fig.1 Human prostate specific antigen (PSA/KLK3) with
bound substrate from complex with antibody.1 Prostate cancer is the most common cancer in Western society, but there remains no reliable and widely available method to distinguish high-risk tumors at an early curable stage. The PSA test has been used for this purpose.
Elevated PSA levels may indicate prostate cancer, a noncancerous condition such as prostatitis, or an enlarged prostate. In addition to prostate cancer, a number of benign (not cancerous) conditions can cause a man's PSA level to rise. The most frequent benign prostate conditions that cause an elevation in PSA level are prostatitis (inflammation of the prostate) and benign prostatic hyperplasia (BPH) (enlargement of the prostate). There is no evidence that prostatitis or BPH leads to prostate cancer, but it is possible for a man to have one or both of these conditions and to develop prostate cancer as well.
PSA tests are an important part of monitoring prostate cancer during and after treatment. In men just diagnosed with prostate cancer, the PSA test can be used together with physical exam results and tumor grade to help decide if other tests (such as CT scans or bone scans) are needed. The PSA test is also a part of staging and can help tell if the cancer is likely to still be confined to the prostate gland.
Based on our state-of-the-art IVD platform, Creative Biolabs offers biomarker-specific antibody development services and immunoassay development services targeting different disease biomarkers to our clients, including PSA. We know that high-quality antibodies are essential elements for immunoassay development and we help develop and screen suitable antibody pairs. For immunoassay development, we help choose the assay format, gather the right components, and construct a good working protocol.
With experts focused on IVD antibody discovery for years, Creative Biolabs is therefore confident in offering the most suitable service and finest results to our customers all over the world. If you are interested in our IVD antibody discovery services, please contact us for more details.
Reference
For Research Use Only.
